Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.

Tytuł:
'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.
Autorzy:
Collins J; UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK .
Westerveld R; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Nelson KA; Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.
Rohan H; UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK.
Bower H; UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK.
Lazenby S; Gates Ventures, Kirkland, Washington, USA.
Ikilezi G; Gates Ventures, Kirkland, Washington, USA.
Bartlein R; Gates Ventures, Kirkland, Washington, USA.
Bausch DG; UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK.
Kennedy DS; UK Public Health Rapid Support Team, London School of Hygiene & Tropical Medicine/Public Health England, London, UK.
Źródło:
BMJ global health [BMJ Glob Health] 2021 Sep; Vol. 6 (9).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
Język:
English
Imprint Name(s):
Original Publication: [London] : BMJ Publishing Group Ltd, [2016]-
MeSH Terms:
COVID-19*
Ebola Vaccines*
Hemorrhagic Fever, Ebola*/epidemiology
Hemorrhagic Fever, Ebola*/prevention & control
Meningitis*
Yellow Fever*/epidemiology
Yellow Fever*/prevention & control
Adult ; COVID-19 Vaccines ; Humans ; Immunization Programs ; SARS-CoV-2
References:
Future Microbiol. 2020 Jan;15:85-106. (PMID: 32030996)
BMC Res Notes. 2015 Apr 14;8:145. (PMID: 25884186)
Vaccine. 2020 Aug 18;38(37):5905-5913. (PMID: 32703746)
Bull World Health Organ. 2003;81(10):726-31. (PMID: 14758432)
Vaccine. 2014 Nov 12;32(48):6505-12. (PMID: 25261379)
Vaccine. 2012 May 30;30 Suppl 2:B40-5. (PMID: 22607898)
Vaccine. 2019 Nov 15;37(48):7165-7170. (PMID: 31623917)
Hum Vaccin Immunother. 2013 Apr;9(4):879-88. (PMID: 23364472)
BMC Public Health. 2020 Feb 19;20(1):254. (PMID: 32075630)
N Engl J Med. 2016 Jul 28;375(4):301-3. (PMID: 27276108)
BMC Public Health. 2020 Jul 14;20(1):1108. (PMID: 32664849)
BMJ Open. 2021 May 28;11(5):e044111. (PMID: 34049907)
PLoS Negl Trop Dis. 2018 Apr 9;12(4):e0006409. (PMID: 29630594)
Lancet Microbe. 2021 Jan;2(1):e1. (PMID: 33521732)
Mem Inst Oswaldo Cruz. 2018 Sep 03;113(10):e180278. (PMID: 30427974)
Vaccine. 2011 Dec 30;29 Suppl 4:D74-9. (PMID: 22486980)
Lancet. 2014 Jan 4;383(9911):40-47. (PMID: 24035220)
Vaccine. 2014 Mar 14;32(13):1431-5. (PMID: 24559895)
BMC Med Ethics. 2016 Feb 08;17:10. (PMID: 26857351)
Vaccine. 2018 Jun 7;36(24):3421-3422. (PMID: 28760613)
NPJ Vaccines. 2021 Apr 14;6(1):54. (PMID: 33854072)
Bull World Health Organ. 2011 Nov 1;89(11):821-830B. (PMID: 22084528)
Vaccine. 2018 Jun 18;36(26):3747-3755. (PMID: 29779921)
Glob Public Health. 2020 Jan;15(1):13-21. (PMID: 31237180)
Harv Public Health Rev (Camb). 2020 Fall;28:. (PMID: 33409499)
PLoS One. 2013 May 09;8(5):e63605. (PMID: 23671685)
Vaccine. 2019 Nov 15;37(48):7183-7189. (PMID: 29074200)
J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S148-S154. (PMID: 31671453)
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S451-8. (PMID: 26553674)
Vaccine. 2020 Jan 16;38(3):470-481. (PMID: 31767469)
Health Policy Plan. 2017 Nov 1;32(suppl_4):iv6-iv12. (PMID: 29194541)
JAMA. 2017 Nov 7;318(17):1651-1652. (PMID: 28983553)
BMJ. 2020 Dec 15;371:m4750. (PMID: 33323376)
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S391-5. (PMID: 26553665)
Lancet Infect Dis. 2020 Dec;20(12):1418-1425. (PMID: 32653071)
Global Health. 2018 Oct 22;14(1):100. (PMID: 30348183)
BMC Public Health. 2017 Feb 15;17(1):200. (PMID: 28202001)
Expert Rev Vaccines. 2019 Feb;18(2):119-131. (PMID: 30689472)
NPJ Vaccines. 2020 Jun 15;5(1):51. (PMID: 32566261)
Expert Rev Vaccines. 2015;14(11):1397-400. (PMID: 26190046)
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S467-72. (PMID: 26553676)
Nat Hum Behav. 2021 Jul;5(7):947-953. (PMID: 33972767)
BMJ Glob Health. 2021 Jan;6(1):. (PMID: 33452138)
Lancet. 2021 Feb 27;397(10276):777-778. (PMID: 33607000)
Sci Transl Med. 2019 Jul 3;11(499):. (PMID: 31270270)
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S434-41. (PMID: 26553672)
Lancet Glob Health. 2020 Jul;8(7):e901-e908. (PMID: 32405459)
N Engl J Med. 2018 Aug 16;379(7):603-605. (PMID: 29995585)
Expert Rev Vaccines. 2013 Dec;12(12):1465-78. (PMID: 24195483)
Vaccines (Basel). 2019 Nov 08;7(4):. (PMID: 31717289)
J Infect Dis. 2018 May 18;217(suppl_1):S48-S55. (PMID: 29788339)
PLoS Negl Trop Dis. 2019 Aug 19;13(8):e0007661. (PMID: 31425507)
Cochrane Database Syst Rev. 2016 Jul 10;7:CD008145. (PMID: 27394698)
PLoS Negl Trop Dis. 2015 Jun 15;9(6):e0003838. (PMID: 26076007)
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S442-50. (PMID: 26553673)
BMJ Glob Health. 2021 Jul;6(7):. (PMID: 34230065)
Vaccine. 2012 Nov 6;30(48):6859-63. (PMID: 22989686)
Front Public Health. 2016 Nov 21;4:254. (PMID: 27917377)
Vaccine. 2019 Nov 15;37(48):7171-7177. (PMID: 30266489)
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15. (PMID: 29788345)
Contributed Indexing:
Keywords: COVID-19; control strategies; immunisation; qualitative study
Substance Nomenclature:
0 (COVID-19 Vaccines)
0 (Ebola Vaccines)
Entry Date(s):
Date Created: 20210918 Date Completed: 20210923 Latest Revision: 20220531
Update Code:
20240105
PubMed Central ID:
PMC8450956
DOI:
10.1136/bmjgh-2021-006951
PMID:
34535490
Czasopismo naukowe
Introduction: COVID-19 vaccines are now being distributed to low- and middle-income countries (LMICs), with global urgency surrounding national vaccination plans. LMICs have significant experience implementing vaccination campaigns to respond to epidemic threats but are often hindered by chronic health system challenges. We sought to identify transferable lessons for COVID-19 vaccination from the rollout of three vaccines that targeted adult groups in Africa and South America: MenAfriVac (meningitis A); 17D (yellow fever) and rVSV-ZEBOV (Ebola virus disease).
Methods: We conducted a rapid literature review and 24 semi-structured interviews with technical experts who had direct implementation experience with the selected vaccines in Africa and South America. We identified barriers, enablers, and key lessons from the literature and from participants' experiences. Interview data were analysed thematically according to seven implementation domains.
Results: Participants highlighted multiple components of vaccination campaigns that are instrumental for achieving high coverage. Community engagement is an essential and effective tool, requiring dedicated time, funding and workforce. Involving local health workers is a key enabler, as is collaborating with community leaders to map social groups and tailor vaccination strategies to their needs. Vaccination team recruitment and training strategies need to be enhanced to support vaccination campaigns. Although recognised as challenging, integrating vaccination campaigns with other routine health services can be highly beneficial if well planned and coordinated across health programmes and with communities.
Conclusion: As supplies of COVID-19 vaccines become available to LMICs, countries need to prepare to efficiently roll out the vaccine, encourage uptake among eligible groups and respond to potential community concerns. Lessons from the implementation of these three vaccines that targeted adults in LMICs can be used to inform best practice for COVID-19 and other epidemic vaccination campaigns.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies